Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azintamide is a small molecule choleretic agent used primarily for the treatment of dyspepsia and biliary tract disorders. It functions by stimulating the secretion of bile from the liver, which aids in the digestion and absorption of lipids. Beyond its choleretic properties, azintamide has been shown to modulate visceral sensitivity and gastrointestinal motility, helping to alleviate symptoms such as upper abdominal bloating, pain, and loss of appetite. It is frequently administered as enteric-coated tablets, often in combination with digestive enzymes like pancreatin to provide comprehensive relief for functional dyspepsia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azintamide.